메뉴 건너뛰기




Volumn 7, Issue A, 2005, Pages

Under-treated high-risk patients: Identifying patients in high-risk subgroups and treating them to LDL-C targets

Author keywords

Adult Treatment Panel III guidelines; Cholesterol lowering; Coronary heart disease; Metabolic syndrome; Peripheral arterial disease; Type 2 diabetes

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; STATINE DERIVATIVE;

EID: 15944393211     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sui004     Document Type: Conference Paper
Times cited : (6)

References (27)
  • 1
    • 0035897696 scopus 로고    scopus 로고
    • Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
    • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
    • (2001) JAMA , vol.285 , pp. 2486-2497
  • 2
    • 0037126526 scopus 로고    scopus 로고
    • Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report
    • National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
    • (2002) Circulation , vol.106 , pp. 3143-3421
  • 3
    • 0026501734 scopus 로고
    • Mortality over a period of 10 years in patients with peripheral arterial disease
    • Criqui MH, Langer RD, Fronek A et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381-386.
    • (1992) N Engl J Med , vol.326 , pp. 381-386
    • Criqui, M.H.1    Langer, R.D.2    Fronek, A.3
  • 4
    • 0018590304 scopus 로고
    • The LDL receptor locus and the genetics of familial hypercholesterolemia
    • Goldstein JL, Brown MS. The LDL receptor locus and the genetics of familial hypercholesterolemia. Annu Rev Genet 1979;13:259-289.
    • (1979) Annu Rev Genet , vol.13 , pp. 259-289
    • Goldstein, J.L.1    Brown, M.S.2
  • 5
    • 0033550469 scopus 로고    scopus 로고
    • When should patients with heterozygous familial hypercholesterolemia be treated?
    • Rifkind BM, Schucker B, Gordon DJ. When should patients with heterozygous familial hypercholesterolemia be treated? JAMA 1999;281:180-181.
    • (1999) JAMA , vol.281 , pp. 180-181
    • Rifkind, B.M.1    Schucker, B.2    Gordon, D.J.3
  • 6
    • 0020472786 scopus 로고
    • The LDL receptor defect in familial hypercholesterolemia implications for pathogenesis and therapy
    • Goldstein JL, Brown MS. The LDL receptor defect in familial hypercholesterolemia. implications for pathogenesis and therapy. Med Clin North Am 1982;66:335-362.
    • (1982) Med Clin North Am , vol.66 , pp. 335-362
    • Goldstein, J.L.1    Brown, M.S.2
  • 7
    • 0026762806 scopus 로고
    • Familial lipoprotein disorders in patients with premature coronary artery disease
    • Genest JJ Jr, Martin-Munley SS, McNamara JR et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992;85:2025-2033.
    • (1992) Circulation , vol.85 , pp. 2025-2033
    • Genest Jr., J.J.1    Martin-Munley, S.S.2    McNamara, J.R.3
  • 8
    • 0027301629 scopus 로고
    • Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics
    • Williams RR, Hunt, SC, Schumacher MC et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 1993;72:171-176.
    • (1993) Am J Cardiol , vol.72 , pp. 171-176
    • Williams, R.R.1    Hunt, S.C.2    Schumacher, M.C.3
  • 9
    • 0242544064 scopus 로고    scopus 로고
    • Comparison of rosuvastatin vs. atorvastatin in patients with heterozygous familial hypercholesterolemia
    • Stein EA, Strutt K, Southworth H et al. Comparison of rosuvastatin vs. atorvastatin in patients with heterozygous familial hypercholesterolemia. Am J Cardiol 2003;92:1287-1293.
    • (2003) Am J Cardiol , vol.92 , pp. 1287-1293
    • Stein, E.A.1    Strutt, K.2    Southworth, H.3
  • 10
    • 3142717531 scopus 로고    scopus 로고
    • Efficacy and safety of statin therapy in children with familial hypercholesterolemia: A randomized controlled trial
    • Wiegman A, Hutten BA, de Groot E et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 2004;292:331-337.
    • (2004) JAMA , vol.292 , pp. 331-337
    • Wiegman, A.1    Hutten, B.A.2    De Groot, E.3
  • 11
    • 0018750365 scopus 로고
    • Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham study
    • Kannel W, McGee D. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 1979;2:120-126.
    • (1979) Diabetes Care , vol.2 , pp. 120-126
    • Kannel, W.1    McGee, D.2
  • 12
    • 0042512336 scopus 로고    scopus 로고
    • Executive summary. European guidelines on cardiovascular disease prevention in clinical practice
    • Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Executive summary. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003;24:1601-1610.
    • (2003) Eur Heart J , vol.24 , pp. 1601-1610
  • 13
    • 0032560807 scopus 로고    scopus 로고
    • Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
    • Haffner SM, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234.
    • (1998) N Engl J Med , vol.339 , pp. 229-234
    • Haffner, S.M.1    Lehto, S.2    Ronnemaa, T.3
  • 14
    • 0037031061 scopus 로고    scopus 로고
    • MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial
    • Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
    • (2002) Lancet , vol.360 , pp. 7-22
  • 15
    • 0037840242 scopus 로고    scopus 로고
    • MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomized placebo-controlled trial
    • Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 2003;361:2005-2016.
    • (2003) Lancet , vol.361 , pp. 2005-2016
  • 17
    • 15944417347 scopus 로고    scopus 로고
    • Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes
    • Abstract M513
    • Franken A, Wolffenbuttel B, Vincent H. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes. (Abstract M513). Atheroscler Suppl 2004;5:118.
    • (2004) Atheroscler Suppl , vol.5 , pp. 118
    • Franken, A.1    Wolffenbuttel, B.2    Vincent, H.3
  • 18
    • 15944400526 scopus 로고    scopus 로고
    • Effect of rosuvastatin and atorvastatin on LDL-C and CRP levels in patients with type 2 diabetes: Results of the ANDROMEDA study
    • Poster presentation; April 17-21; Seville, Spain
    • Betteridge J, Gibson M, on behalf of the ANDROMEDA study investigators. Effect of rosuvastatin and atorvastatin on LDL-C and CRP levels in patients with type 2 diabetes: results of the ANDROMEDA study. Poster presentation at: the 74th European Atherosclerosis Society Congress; April 17-21, 2004; Seville, Spain.
    • (2004) The 74th European Atherosclerosis Society Congress
    • Betteridge, J.1    Gibson, M.2
  • 19
    • 0037021505 scopus 로고    scopus 로고
    • The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men
    • Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-2716.
    • (2002) JAMA , vol.288 , pp. 2709-2716
    • Lakka, H.M.1    Laaksonen, D.E.2    Lakka, T.A.3
  • 20
    • 0037157596 scopus 로고    scopus 로고
    • Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: A prospective study
    • Norhammer A, Tenerz A, Nilsson G et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002;359:2140-2144.
    • (2002) Lancet , vol.359 , pp. 2140-2144
    • Norhammer, A.1    Tenerz, A.2    Nilsson, G.3
  • 21
    • 0035910051 scopus 로고    scopus 로고
    • Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S
    • Ballantyne CM, Olsson AG, Cook TJ et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001;104:3046-3051.
    • (2001) Circulation , vol.104 , pp. 3046-3051
    • Ballantyne, C.M.1    Olsson, A.G.2    Cook, T.J.3
  • 22
    • 0042665536 scopus 로고    scopus 로고
    • Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study
    • Sattar N, Gaw A, Scherbakova O et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414-419.
    • (2003) Circulation , vol.108 , pp. 414-419
    • Sattar, N.1    Gaw, A.2    Scherbakova, O.3
  • 23
    • 0037526450 scopus 로고    scopus 로고
    • Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome
    • Wong ND, Pio JR, Franklin SS et al. Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. Am J Cardiol 2003;91:1421-1426.
    • (2003) Am J Cardiol , vol.91 , pp. 1421-1426
    • Wong, N.D.1    Pio, J.R.2    Franklin, S.S.3
  • 24
    • 2642539095 scopus 로고    scopus 로고
    • Effects of lipid-altering treatment in diabetes mellitus and the metabolic syndrome
    • Deedwania PC, Hunninghake DB, Bays H. Effects of lipid-altering treatment in diabetes mellitus and the metabolic syndrome. Am J Cardiol 2004;93(Suppl.):18C-26C.
    • (2004) Am J Cardiol , vol.93 , Issue.SUPPL.
    • Deedwania, P.C.1    Hunninghake, D.B.2    Bays, H.3
  • 25
    • 2642526397 scopus 로고    scopus 로고
    • Efficacy of atorvastatin in dyslipidemic patients with metabolic syndrome in the ACCESS study
    • Abstract 2141-PO
    • Newman C, Hopkinson C, Messig M et al. Efficacy of atorvastatin in dyslipidemic patients with metabolic syndrome in the ACCESS study. (Abstract 2141-PO). Diabetes 2003;52(Suppl. 1):A494.
    • (2003) Diabetes , vol.52 , Issue.SUPPL. 1
    • Newman, C.1    Hopkinson, C.2    Messig, M.3
  • 26
    • 85071830772 scopus 로고    scopus 로고
    • Comparison of rosuvastatin with atorvastatin, simvastatin, and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholestrolaemic patients with or without the metabolic syndrome (MERCURY I trial)
    • in press
    • Slender S, Schuster H, Barter P et al. Comparison of rosuvastatin with atorvastatin, simvastatin, and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholestrolaemic patients with or without the metabolic syndrome (MERCURY I trial). Diabetes Obes Metab, in press.
    • Diabetes Obes Metab
    • Slender, S.1    Schuster, H.2    Barter, P.3
  • 27
    • 3142729178 scopus 로고    scopus 로고
    • Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
    • Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-239.
    • (2004) Circulation , vol.110 , pp. 227-239
    • Grundy, S.M.1    Cleeman, J.I.2    Merz, C.N.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.